Nature Medicine
4, 757 - 759 (1998)
doi:10.1038/nm0798-757
Genetic testing and Alzheimer disease: Has the time come?L.M. McConnell1, 2, B.A. Koenig1, H.T. Greely1
& T.A. Raffin1
1Stanford University Program in Genomics, Ethics, and Society, 701 Welch Road, Suite 1105, Palo Alto, California 94304 USA
2Correspondence should be addressed to L.M. e-mail: lauramcc@leland.stanford.edu With the identification of several Alzheimer disease (AD)-associated genes, genetic testing for AD is possible. However, as for some other-late onset disorders, the ethical and social implications of such tests are considerable. In response to the commercial availability and the likely increased use of AD genetic tests, The Stanford Program in Genomics, Ethics, and Society formed a broad-based working group to examine the pros and cons of testing. Here they present their recommendations.
REFERENCES
- Butler, R.N. ApoE: new risk factor for Alzheimer's [editorial]. Geriatrics 49 10−11 (1994). | ISI |
- American College of Medical Genetics, American Society of Human Genetics & Working Group on ApoE and Alzheimer Disease. Statement on use of apolipoprotein E testing for Alzheimer disease. J. Am. Med. Assoc. 274, 1627−1629 (1995). | ISI |
- Medical and Scientific Advisory Committee & Alzheimer's Disease International. Consensus statement on predictive testing for Alzheimer disease. Alzheimer Dis Assoc. Disord. 9, 182−187 (1996). | ISI |
- National Institute on Aging & Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 347, 1091−1095 (1996). | PubMed | ISI |
- Post, S.G. et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. J. Am. Med. Assoc. 227, 832−836 (1997). | Article |
- Holtzman, N.A. & Hilgartner, S. Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. (eds Holtzman, N.A. & Watson, M.S.) (National Institutes of Health, Washington, DC, 1997).
- Koenig, B. et al. Genetic testing for BRCA1 and BRCA2: Recommendations of the Stanford Program in Genomics, Ethics, and Society. J. Womens Health 7, 531−545 (1998). | PubMed | ISI | ChemPort |
- Lehrman, S. Genetic testing for Alzheimer's disease 'not appropriate'. Nature 389, 898 (1997). | Article | PubMed | ISI | ChemPort |
- Schofield, P.W. et al. Alzheimer's disease after remote head injury: an incidence study. J. Neurol. Neurosurg. Psychiatry 62, 119−124 (1997). | PubMed | ISI | ChemPort |
- Farrer, L.A. Genetics and the dementia patient. Neurologist 3, 13−30 (1997). | ISI |
- International Huntington Association & World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 44, 1533−1536 (1994). | ISI |
- Roses, A.D. Apolipoprotein E and Alzheimer's disease: a rapidly expanding field with medical and epidemiological consequences. Ann. NYAcad. Sci. 802, 50−57 (1996). | ChemPort |
- Mayeux, R. Saunders, A.M. Shea, S. Mirra, S. & et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N. Engl. J. Med. 338, 506−511 (1998). | Article | PubMed | ISI | ChemPort |
|
